FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2210275433> ?p ?o ?g. }

• W2210275433 endingPage "378" @default.
• W2210275433 startingPage "S" @default.
• W2210275433 abstract "Background and Aims: VSL#3 is a high potency probiotic mixture containing eight bacterial strains. Recent data demonstrates that VSL#3 is able to induce and maintain remission of ulcerative colitis (Danese & Fiocchi NEJM, 2011;365:1713-25). However, the role of this agent in pediatric Crohn disease (CD) has not yet been evaluated. The primary aim of this study was to assess the role of VSL#3 in the induction of remission of children with active CD: secondary end-points were clinical response, weight z scores and haematological parameters. Methods: A randomised, double-blind, placebo-controlled, cross-over study was conducted in two Australian pediatric centres. Children with active CD (based upon Pediatric Crohn disease activity Index (PCDAI) scores) and aged between 4 and 18 years were recruited. Participants were randomised to receive a 3 month period of active probiotic followed by 3 months of placebo (or in the reverse order), with a one month washout between each arm. Standard dose of VSL#3 was 1,800 billion organisms daily, with adjustment for age. Outcomes included PCDAI scores, serum and faecal inflammatory markers and growth parameters. Results: Seventeen children completed the study and were available for evaluation. The mean PCDAI scores at enrolment were 22.3 ± 7 (ranging from 15 to 40).At the start of month 4, just five children had PCDAI scores greater than 15. Four children in both groups had response (PCDAI fell by 12.5 or more) or entered remission (PCDAI <15). In the subset with active disease at the start of probiotic therapy (whether at month 0 or 4), PCDAI scores fell from 24.6 ± 9 to 12 ± 11.2 (p=0.007). Serum albumin levels increased during treatment with probiotics (2 ± 2.4 g/l) but fell with placebo (0.8 ± 2.7 g/l): p=0.024). Weight z scores also improved by 0.15 ± 0.08 with probiotic treatment but fell by 0.14 ±0.06 in the placebo group (p=0.025). Conclusions: VSL#3 therapy in children with active CD has a significant beneficial effect upon disease activity, along with improvements in weight and albumin. Considering the importance of disease control and nutrition in the management of children with CD, further studies of this probiotic agent in larger groups of children are justified." @default.
• W2210275433 created "2016-06-24" @default.
• W2210275433 creator A5006726610 @default.
• W2210275433 creator A5009371773 @default.
• W2210275433 creator A5009432009 @default.
• W2210275433 creator A5011889522 @default.
• W2210275433 creator A5019018783 @default.
• W2210275433 creator A5027114606 @default.
• W2210275433 creator A5041630868 @default.
• W2210275433 creator A5051120488 @default.
• W2210275433 creator A5051655433 @default.
• W2210275433 creator A5058101509 @default.
• W2210275433 creator A5067402350 @default.
• W2210275433 creator A5071195198 @default.
• W2210275433 creator A5080059330 @default.
• W2210275433 date "2012-05-01" @default.
• W2210275433 modified "2023-10-04" @default.
• W2210275433 title "Sa2001 Longitudinal Assessment of Health-Related Quality of Life in Pediatric Inflammatory Bowel Disease" @default.
• W2210275433 doi "https://doi.org/10.1016/s0016-5085(12)61427-9" @default.
• W2210275433 hasPublicationYear "2012" @default.
• W2210275433 type Work @default.
• W2210275433 sameAs 2210275433 @default.
• W2210275433 citedByCount "0" @default.
• W2210275433 crossrefType "journal-article" @default.
• W2210275433 hasAuthorship W2210275433A5006726610 @default.
• W2210275433 hasAuthorship W2210275433A5009371773 @default.
• W2210275433 hasAuthorship W2210275433A5009432009 @default.
• W2210275433 hasAuthorship W2210275433A5011889522 @default.
• W2210275433 hasAuthorship W2210275433A5019018783 @default.
• W2210275433 hasAuthorship W2210275433A5027114606 @default.
• W2210275433 hasAuthorship W2210275433A5041630868 @default.
• W2210275433 hasAuthorship W2210275433A5051120488 @default.
• W2210275433 hasAuthorship W2210275433A5051655433 @default.
• W2210275433 hasAuthorship W2210275433A5058101509 @default.
• W2210275433 hasAuthorship W2210275433A5067402350 @default.
• W2210275433 hasAuthorship W2210275433A5071195198 @default.
• W2210275433 hasAuthorship W2210275433A5080059330 @default.
• W2210275433 hasBestOaLocation W22102754331 @default.
• W2210275433 hasConcept C126322002 @default.
• W2210275433 hasConcept C142724271 @default.
• W2210275433 hasConcept C159110408 @default.
• W2210275433 hasConcept C187212893 @default.
• W2210275433 hasConcept C204787440 @default.
• W2210275433 hasConcept C27081682 @default.
• W2210275433 hasConcept C2778260677 @default.
• W2210275433 hasConcept C2779134260 @default.
• W2210275433 hasConcept C2779280984 @default.
• W2210275433 hasConcept C2779951463 @default.
• W2210275433 hasConcept C2780255968 @default.
• W2210275433 hasConcept C2780479503 @default.
• W2210275433 hasConcept C523546767 @default.
• W2210275433 hasConcept C535046627 @default.
• W2210275433 hasConcept C54355233 @default.
• W2210275433 hasConcept C71924100 @default.
• W2210275433 hasConcept C86803240 @default.
• W2210275433 hasConcept C90924648 @default.
• W2210275433 hasConceptScore W2210275433C126322002 @default.
• W2210275433 hasConceptScore W2210275433C142724271 @default.
• W2210275433 hasConceptScore W2210275433C159110408 @default.
• W2210275433 hasConceptScore W2210275433C187212893 @default.
• W2210275433 hasConceptScore W2210275433C204787440 @default.
• W2210275433 hasConceptScore W2210275433C27081682 @default.
• W2210275433 hasConceptScore W2210275433C2778260677 @default.
• W2210275433 hasConceptScore W2210275433C2779134260 @default.
• W2210275433 hasConceptScore W2210275433C2779280984 @default.
• W2210275433 hasConceptScore W2210275433C2779951463 @default.
• W2210275433 hasConceptScore W2210275433C2780255968 @default.
• W2210275433 hasConceptScore W2210275433C2780479503 @default.
• W2210275433 hasConceptScore W2210275433C523546767 @default.
• W2210275433 hasConceptScore W2210275433C535046627 @default.
• W2210275433 hasConceptScore W2210275433C54355233 @default.
• W2210275433 hasConceptScore W2210275433C71924100 @default.
• W2210275433 hasConceptScore W2210275433C86803240 @default.
• W2210275433 hasConceptScore W2210275433C90924648 @default.
• W2210275433 hasIssue "5" @default.
• W2210275433 hasLocation W22102754331 @default.
• W2210275433 hasOpenAccess W2210275433 @default.
• W2210275433 hasPrimaryLocation W22102754331 @default.
• W2210275433 hasRelatedWork W1797212104 @default.
• W2210275433 hasRelatedWork W2069986433 @default.
• W2210275433 hasRelatedWork W2072664568 @default.
• W2210275433 hasRelatedWork W2074958075 @default.
• W2210275433 hasRelatedWork W2083481365 @default.
• W2210275433 hasRelatedWork W2124822229 @default.
• W2210275433 hasRelatedWork W2291478289 @default.
• W2210275433 hasRelatedWork W2328012130 @default.
• W2210275433 hasRelatedWork W2462250829 @default.
• W2210275433 hasRelatedWork W2583263803 @default.
• W2210275433 hasRelatedWork W2765495405 @default.
• W2210275433 hasRelatedWork W2892718958 @default.
• W2210275433 hasRelatedWork W2960103696 @default.
• W2210275433 hasRelatedWork W2981168365 @default.
• W2210275433 hasRelatedWork W2985852505 @default.
• W2210275433 hasRelatedWork W3027071520 @default.
• W2210275433 hasRelatedWork W3088386202 @default.
• W2210275433 hasRelatedWork W3108180053 @default.
• W2210275433 hasRelatedWork W3197632780 @default.
• W2210275433 hasRelatedWork W3199437348 @default.

• next